1. Gibbon JH JR. The development of the heart-lung apparatus. Am J Surg. 1978; 135: 608-619.
2. 井上 正. ⼼臓⼤⾎管外科の歴史と展望. 臨床外科. 1989; 50: 447-453.
3. Committee for Scientific Affairs. Thoracic and cardiovascular surgery in Japan in 2016. annual report by the japanese association for thoracic Surgery. Gen Thorac Cardiovasc Surg. 2019; 67: 377-411.
4. Sniecinski RM, Levy JH. Anticoagulation management associated with extracorporeal circulation. Best Pract Res Clin Anaesthesiol. 2015; 29: 189- 202.
5. Shore-Lesserson L, Baker RA, Ferraris V, et al. STS/SCA/AmSECT clinical practice guidelines: anticoagulation during cardiopulmonary bypass. J Extra Corpor Technol. 2018; 50: 5–18.
6. Kehara H, Takano T, Ohashi N, T et al. Pletelet function during cardiopulmonary bypass using multiple electrode aggregometry: comparison of centrifugal and roller pump. Artif Organs. 2014; 38: 924-930.
7. Demirtas H, Iriz E, Demirtas CY, et al. Investigating the effects of two different pump heads (centrifugal vs. roller pump) on hematological and immunological mechanisms. Niger J Clin Pract. 2018; 21: 847-853.
8. Kolff WJ, Effler DB, Groves LK. Pulmonary complications of open heart operations: their pathogenesis and avoidance. Cleve Clin Q. 1958; 25: 65-83.
9. Asimakopoulos G, Taylor KM, Smith PL, et al. Prevalence of acute respiratory distress syndrome after cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1999; 117: 620-621.
10. Gott JP, Cooper WA, Schmidt FE Jr, et al. Modifying risk for extracorporeal circulation: trial of four anti-inflammatory strategies. Ann Thorac Surg. 1998; 66: 747-753.
11. Brister SJ, Ofosu FA, Buchanan MR. Thrombin generation during cardiac surgery: is heparin the ideal anticoagulant? Thromb Haemost. 1993; 70: 259-262.
12. Heyer EJ, Lee KS, Manspeizer HE, et al. Heparin-bonded cardiopulmonary bypass circuits reduce cognitive dysfunction. J Cardiothorac Vasc Anesth. 2002; 16: 37-42.
13. Pappalardo F, Della Valle P, Crescenzi G, et al. Phosphorycholine coating may limit thrombin formation during high-risk cardiac surgery: a randomized controlled trial. Ann Thorac Surg. 2006; 81: 886-891.
14. Tanaka M, Motomura T, Kawada M, et al. Blood compatible aspects of poly (2-methoxyethylacrylate) (PMEA)–relationship between protein adsorption and platelet adhesion on PMEA surface. Biomaterials. 2000; 21: 1471-1481.
15. Hoel T, Videm V, Baksaas ST, et al. Comparison of a Duraflo II-coated cardiopulmonary bypass circuit and a trillium-coated oxygenator during open-heart surgery. Perfusion. 2004; 19: 177-184.
16. Belway D, Rubens FD. Currently available biomaterials for use in cardiopulmonary bypass. Expert Rev Med Devices. 2006; 3: 345-355.
17. Lui M, Gardiner EE, Arthur JE, et al. Novel stenotic microchannels to study thrombus formation in shear gradients: influence of shear forces and human platelet-related factors. Int J Mol Sci. 2019; 20: 2967.
18. Nesbitt WS, Westein E, Tovar-Lopez FJ, et al. A shear gradient–dependent platelet aggregation mechanism drives thrombus formation. Nat Med. 2009; 15: 665-673.
19. Koliopoulou A, McKellar SH, Rondina M, et al. Bleeding and thrombosis in chronic ventricular assist device therapy: focus on platelets. Curr Opin Cardiol. 2016; 31: 299-307.
20. Hu J, Mondal NK, Sorensen EN, et al. Platelet glycoprotein Ib ectodomain shedding and non-surgical bleeding in heart failure patients supported by continuous-flow left ventricular assist devices. J Heart Lung Transplant. 2014; 33: 71-79.
21. Stulak JM, Davis ME, Haglund N, et al. Adverse events in contemporary continuous-flow left ventricular assist devices: a multi-institutional comparison shows significant differences. J Thorac Cardiovasc Surg. 2016; 151: 177-189.
22. Susen A, Rauch A, Van Belle E, et al. Circulatory support devices: fundamental aspects and clinical management of bleeding and thrombosis. J Thromb Haemost. 2015; 13: 1757-1767.
23. Heilmann C, Trummer G, Beyersdorf F, et al. Acquired von Willebrand syndrome in patients on long-term support with HeartMate II. Eur J Cardiothorac Surg. 2017; 51: 587-590.
24. Deconinck S, Tersteeg C, Bailleul E, et al. Differences in von Willebrand factor function in type 2A von Willebrand disease and left ventricular assist device- induced acquired von Willebrand syndrome. Res Pract Thromb Haemost. 2018; 2: 762-766.
25. Davis ME, Haglund NA, Tricarico NM, et al. Development of acquired von Willebrand syndrome during short-term micro axial pump support: implications for bleeding in a patient bridged to a long-term continuous-flow left ventricular assist device. ASAIO J. 2014; 60: 355-357.
26. Kubicki R, Stiller B, Kroll J, et al. Acquired von Willebrand syndrome in paediatric patients during mechanical circulatory support. Eur J Cardiothorac Surg. 2019; 55: 1194-1201.
27. Ki KK, Passmore MR, Chan CHH, et al. Low flow rate alters haemostatic parameters in an ex-vivo extracorporeal membrane oxygenation circuit. Intensive Care Med Exp. 2019; 7: 51.
28. 坂⽖ 公. 補助⼈⼯⼼臓患者における後天性フォンウイルブランド症候群. ⾎栓⽌⾎誌. 2019; 30: 660-668.
29. Geisen U, Brehm K, Trummer G, et al. Platelet secretion defects and acquired von Willebrand syndrome in patients with ventricular assist devices. J Am Heart Assoc. 2018; 7: e006519.
30. Soo A, Booth K, Parissis H. Successful management of membrane oxygenator failure during cardiopulmonary bypass-the importance of safety algorithm and simulation drills. J Extra Corpor Technol. 2012; 44: 78-80.
31. Fisher AR, Baker M, Buffin M, et al. Normal and abnormal trans-oxygenator pressure gradients during cardiopulmonary bypass. Perfusion. 2003; 18: 25-30.
32. 宮⽥ 敏⾏,樋⼝(江浦)由佳,杉本 充彦. ⾎栓形成機序の新概念と次世代型抗⾎栓療法. ⽣化学. 2017; 89: 333-342.
33. Owens AP III, Mackman N. Microparticles in hemostasis and thrombosis. Circ Res. 2011; 108: 1284-1297.
34. Ponomareva AA, Nevzorova TA, Mordakhanova ER, et al. Intracellular origin and ultrastructure of platelet-derived microparticles. J Thromb Haemost. 2017; 15: 1655-1667.
35. Vasina EM, Cauwenberghs S, Staudt M, et al. Aging-and activation-induced platelet microparticles suppress apoptosis in monocytic cells and differentially signal to proinflammatory mediator release. Am J Blood Res. 2013; 3: 107- 123.
36. Pawlowski C, Li W, Sun M, et al. Platelet microparticle-inspired clot- responsive nanomedicine for targeted fibrinolysis. Biomaterials. 2017; 128: 94-108.
37. Boilard E, Duchez AC, Brisson A. The diversity of platelet microparticles. Curr Opin Hematol. 2015; 22: 437-444.
38. Nieuwland R, Sturk A. Why do cells release vesicles?. Thromb Res. 2010; 125 : S49-S51.
39. 杉本 光彦. ⾎栓形成過程: オーバービュー. 脈管学. 2011; 51: 275-282.
40. Ramström S, Södergren A, Tynngård N, et al. Platelet function determined by flow cytometry: new perspectives?. Semin Thromb Hemost. 2016; 42: 268-281.
41. Chen M, Geng JG. P-selectin mediates adhesion of leukocytes, platelets, and cancer cells in inflammation, thrombosis, and cancer growth and metastasis. Arch Immunol Ther Exp. 2006; 54: 75-84.
42. Huang GS, Hu MH, Lin TC, et al. Impact of blood mixing and ABO compatibility on platelet-leukocyte aggregations and platelet P-selectin expression: an in vitro study. Shock. 2018; 49: 514-521.
43. Ghasemzadeh M, Hosseini E. Platelet granule release is associated with reactive oxygen species generation during platelet storage: a direct link between platelet pro-inflammatory and oxidation states. Thromb Res. 2017; 156: 101-104.
44. Nagata S, Sakuragi T, Segawa K. Flippase and scramblase for phosphatidylserine exposure. Curr Opin in Immunol. 2020; 62: 31-38.
45. ⼭崎泰男. 細胞膜リン脂質のスクランブルと⾎液凝固. ⾎栓⽌⾎誌. 2017; 28: 421-428.
46. 鈴⽊ 淳. 細胞膜リン脂質のスクランブル機構. ⽣化学. 2015; 87: 422-427.
47. Varon D, Shai E. Platelets and their microparticles as key players in pathophysiological responses. J Thromb Haemost. 2015; 13 (Suppl. 1): S40- S46.
48. Burnouf T, Goubran HA, Chou ML, et al. Platelet microparticles: detection and assessment of their paradoxical functional roles in disease and regenerative medicine. Blood Rev. 2014; 28: 155-166.
49. Riswari SF, Tunjungputri RN, Kullaya V, et al. Desialylation of platelets induced by von Willebrand factor is a novel mechanism of platelet clearance in dengue. PLoS Pathog. 2019; 15: e1007500.
50. Kullaya V, de Jonge MI, Langereis JD, et al. Desialylation of platelets by pneumococcal neuraminidase a induces ADP-dependent platelet hyperreactivity. Infect Immun. 2018; 86: e00213-18.
51. Li MF, Li XI, Fan KI, et al. Platelet desialylation is a novel mechanism and a therapeutic target in thrombocytopenia during sepsis: an open-label, multicenter, randomized controlled trial. J Hematol Oncol. 2017; 10: 104.
52. Murase M, Nakayama Y, Sessler DI, et al. Changes in platelet Bax levels contribute to impaired platelet response to thrombin after cardiopulmonary bypass: prospective observational clinical and laboratory investigations. Br J Anaesth. 2017; 119: 1118-1126.
53. Mondal NK, Sorensen EN, Hivala NJ, et al. Intraplatelet reactive oxygen species, mitochondrial damage and platelet apoptosis augment non-surgical bleeding in heart failure patients supported by continuous-flow left ventricular assist device. Platelets. 2015; 26: 536-544.
54. Gremmel T, Frelinger AL III, Michelson AD. Platelet physiology. Semin Thromb Hemost. 2016; 42: 191-204.
55. Holinstat M. Normal platelet function. Cancer Metastasis Rev. 2017; 36: 195-198.
56. Li Y, Fu J, Ling Y, et al. Sialylation on O-glycans protects platelets from clearance by liver Kupffer cells. Proc Natl Acad Sci USA. 2017; 114: 8360- 8365.
57. Xu M, Li J, Neves MAD, et al. GPIb is required for platelet-mediated hepatic thrombopoietin generation. Blood. 2018; 132: 622-634.
58. Grozovsky R, Giannini S, Falet H, et al. Regulating billions of blood platelets: glycans and beyond. Blood. 2015; 126: 1877-1884.
59. Hoffmeister KM, Falet H. Platelet clearance by the hepatic ashwell-morrell receptor: mechanisms and biological significance. Thromb Res. 2016; 141(Suppl. 2): S68-S72.
60. Nagata S, Suzuki J, Segawa K, et al. Exposure of phosphatidylserine on the cell surface. Cell Death Differ. 2016; 23: 952-961.
61. Pang A, Cui Y, Chen Y, et al. Shear-induced integrin signaling in platelet phosphatidylserine exposure, microvesicle release, and coagulation. Blood. 2018; 132: 533-543.
62. Bevers EM, Williamson PL. Getting to the outer leaflet: physiology of phosphatidylserine exposure at the plasma membrane. Physiol Rev. 2016; 96: 605-645.
63. Cho J, Kim H, Song J, et al. Platelet storage induces accelerated desialylation of platelets and increases hepatic thrombopoietin production. J Transl Med. 2018; 16: 199.
64. Brisson AR, Tan S, Linares R, et al. Extracellular vesicles from activated platelets: a semiquantitative cryo-electron microscopy and immuno-gold labeling study. Platelets. 2017; 28: 263-271.
65. Halaweish I, Cole A, Cooley E, et al. Roller and centrifugal pumps: a retrospective comparison of bleeding complications in extracorporeal membrane oxygenation. ASAIO J. 2105; 61: 496-501.
66. Reich HJ, Morgan J, Arabia F, et al. Comparative analysis of von Willebrand factor profiles after implantation of left ventricular assist device and total artificial heart. J Thromb Haemost. 2017; 15: 1620–1624.
67. Datt B, Nguyen MB, Plancher G, et al. The impact of roller pump vs. centrifugal pump on homologous blood transfusion in pediatric cardiac surgery. J Extra Corpor Technol. 2017; 49: 36-43.
68. Passaroni AC, Felicio ML, Campos NLKL, et al. Hemolysis and inflammatory response to extracorporeal circulation during on-pump CABG: comparison between roller and centrifugal pump systems. Braz J Cardiovasc Surg. 2018; 33: 64-71.
69. Leytin V. Apoptosis in the anucleate platelet. Blood Rev. 2012; 26: 51-63.
70. Shankaran H, Alexandridis P, Neelamegham S. Aspects of hydrodynamic shear regulating shear-induced platelet activation and self-association of von Willebrand factor in suspension. Blood. 2003; 101: 2637-2645.
71. Nascimbene A, Neelamegham S, Frazier OH, et al. Acquired von Willebrand syndrome associated with left ventricular assist device. Blood. 2016; 127: 3133-3141.
72. Zhou X, Liang XM, Zhao G, et al. A new computational fluid dynamics method for in-depth investigation of flow dynamics in roller pump systems. Artif Organs. 2014; 38: E106-117.
73. Jilma-Stohlawetz P, Quehenberger P, Schima H, et al. Acquired von Willebrand facter deficiency caused by LVAD is ADAMTS-13 and platelet dependent. Thromb Res. 2016; 137: 196-201.
74. Haung XD, Yao K, Zhang H, et al. Surface modification of silicone intraocular lens by 2-methacryloyloxyethyl phosphoryl-choline binding to reduce Staphylococcus epidermidis adherence. Clin Exp Ophthalmol. 2007; 35: 462-467.
75. Kirshbom PM, Miller BE, Spitzer K, et al. Failure of surface-modified bypass circuits to improve platelet function during pediatric cardiac surgery. J Thorac Cardiovasc Surg. 2006; 132: 675-680.
76. Kutay V, Noyan T, Ozcan S, et al. Biocompatibility of heparin-coated cardiopulmonary bypass circuits in coronary patients with left ventricular dysfunction is superior to PMEA-coated circuits. J Card Surg. 2006; 21: 572- 577.
77. Ninomiya M, Miyaji K, Takamoto S. Influence of PMEA-coated bypass circuits on perioperative inflammatory response. Ann Thorac Surg. 2003; 75: 913- 918.
78. Landis RC, Brown JR, Fitzgerald D, et al. Attenuating the systemic inflammatory response to adult cardiopulmonary bypass: a critical review of the evidence base. J Extra Corpor Technol. 2014; 46: 197-211.
79. Gorman RC, Ziats N, Rao AK, et al. Surface-bound heparin fails to reduce thrombin formation during clinical cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1996; 111: 1-11.